Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioNTech SE filings document the disclosures of a foreign private issuer that reports to the SEC primarily through Form 6-K current reports and annual reports on Form 20-F. The records cover interim condensed consolidated financial statements, operating and financial reviews, corporate updates, and exhibit filings related to press releases and investor presentations.
BioNTech’s filings also describe ADS-related capital actions, including repurchase program disclosures for American Depositary Shares representing ordinary shares. Other recurring subjects include annual general meeting invitations and shareholder voting mechanics, governance matters, clinical and regulatory updates for oncology programs, COVID-19 vaccine activity, collaboration-related pipeline information, and material-event disclosures affecting capital allocation and corporate strategy.
BioNTech SE director Helmut Wolfgang Jeggle reported his initial ownership of the company’s ordinary shares. The Form 3 shows he holds 332,316 ordinary shares directly and 656,951 ordinary shares indirectly as of March 18, 2026. The indirect shares are held by Salvia GmbH, where he serves as Chief Executive Officer and may be deemed to beneficially own the shares held by that entity.
BioNTech SE’s Chief Medical Officer, Ozlem Tureci, filed an initial Form 3 disclosing existing equity-based awards, rather than new share purchases or sales. The filing lists option grants over 18,416, 25,459 and 9,306 underlying ordinary shares, phantom options over 7,112 and 14,664 shares, and 11,633 performance share units.
Footnotes explain that these options and PSUs generally vest in equal annual installments over four years and become exercisable four years after grant, subject to performance-based conditions tied to BioNTech’s share price and, for PSUs, its performance relative to the Nasdaq Biotechnology Index.
BioNTech SE director Ulrich Wandschneider filed an initial statement of beneficial ownership. The filing reports indirect beneficial ownership of 1,927 ordinary shares.
The shares are held by beebusy Capital GmbH, where Wandschneider is the sole shareholder and may be deemed to beneficially own the shares. The filing does not report any recent share purchases or sales, only this existing position.
BioNTech SE Chief Commercial Officer Annemarie Hanekamp filed an initial Form 3 reporting derivative equity holdings. She holds an option over 8,838 ordinary shares and performance share units linked to 11,047 ordinary shares. Both awards vest in equal annual installments over four years, subject to performance conditions.
BioNTech SE filed a Form 144 notifying of a proposed sale of 150,000 American Depositary Shares on 03/11/2026 for an aggregate offering price of $12,583,500.00 on the Nasdaq Global Select market. The filing lists underlying sources including 95,000 shares from a stock option exercise and 55,000 shares from a private transaction.
BioNTech files its 2025 Form 20-F annual report, describing its mRNA-focused business, COVID-19 vaccine franchise and expanding oncology and antibody-drug conjugate pipelines. The company highlights extensive regulatory, clinical, manufacturing, competitive and intellectual property risks around developing and commercializing its product candidates.
Revenue is noted as heavily dependent on its COVID-19 vaccine, with demand expected to decrease, while future growth is tied to new oncology assets such as BNT327 and ADCs. BioNTech also discloses operational and geopolitical risks from global trials and supply chains, ESG and human-rights compliance obligations, and AI-related legal and reputational uncertainties. Ordinary shares outstanding were 239,970,804 as of March 3, 2025.
BioNTech files its 2025 Form 20-F annual report, describing its mRNA-focused business, COVID-19 vaccine franchise and expanding oncology and antibody-drug conjugate pipelines. The company highlights extensive regulatory, clinical, manufacturing, competitive and intellectual property risks around developing and commercializing its product candidates.
Revenue is noted as heavily dependent on its COVID-19 vaccine, with demand expected to decrease, while future growth is tied to new oncology assets such as BNT327 and ADCs. BioNTech also discloses operational and geopolitical risks from global trials and supply chains, ESG and human-rights compliance obligations, and AI-related legal and reputational uncertainties. Ordinary shares outstanding were 239,970,804 as of March 3, 2025.
BioNTech reported fourth quarter and full year 2025 results, updated 2026 guidance and outlined a major oncology-focused strategy shift. 2025 revenues were €2.9 billion while the company recorded a net loss of €1.1 billion and adjusted net loss of €0.1 billion. Cash, cash equivalents and security investments totaled €17.2 billion, providing substantial funding for its expanding cancer pipeline.
For 2026, BioNTech expects total revenues of €2.0–2.3 billion, adjusted R&D expenses of €2.2–2.5 billion and adjusted SG&A expenses of €700–800 million as it prioritizes late‑stage oncology development. Management highlighted multiple 2026 data readouts across immunomodulators, antibody‑drug conjugates and mRNA cancer immunotherapies.
The company plans an independent next‑generation mRNA venture to be led by co‑founders Ugur Sahin and Özlem Türeci, who are expected to transition by the end of 2026. BioNTech aims to become a multi‑product oncology company by 2030 with numerous planned late‑stage and potentially registrational trials.
BioNTech reported fourth quarter and full year 2025 results, updated 2026 guidance and outlined a major oncology-focused strategy shift. 2025 revenues were €2.9 billion while the company recorded a net loss of €1.1 billion and adjusted net loss of €0.1 billion. Cash, cash equivalents and security investments totaled €17.2 billion, providing substantial funding for its expanding cancer pipeline.
For 2026, BioNTech expects total revenues of €2.0–2.3 billion, adjusted R&D expenses of €2.2–2.5 billion and adjusted SG&A expenses of €700–800 million as it prioritizes late‑stage oncology development. Management highlighted multiple 2026 data readouts across immunomodulators, antibody‑drug conjugates and mRNA cancer immunotherapies.
The company plans an independent next‑generation mRNA venture to be led by co‑founders Ugur Sahin and Özlem Türeci, who are expected to transition by the end of 2026. BioNTech aims to become a multi‑product oncology company by 2030 with numerous planned late‑stage and potentially registrational trials.
BioNTech SE plans to support the creation of an independent biotechnology company led by co-founders Prof. Ugur Sahin and Prof. Özlem Türeci that will focus on next-generation mRNA innovations. BioNTech intends to contribute related rights and mRNA technologies in return for a minority stake, milestones and royalties.
BioNTech says its current clinical pipeline, including its COVID‑19 vaccine franchise, remains unaffected and expects to have 15 ongoing Phase 3 oncology trials by year end, with multiple late-stage data readouts in 2026. Sahin and Türeci are expected to transition to the new company’s management by the end of 2026, while BioNTech’s Supervisory Board has started searching for their successors.
BioNTech SE plans to support the creation of an independent biotechnology company led by co-founders Prof. Ugur Sahin and Prof. Özlem Türeci that will focus on next-generation mRNA innovations. BioNTech intends to contribute related rights and mRNA technologies in return for a minority stake, milestones and royalties.
BioNTech says its current clinical pipeline, including its COVID‑19 vaccine franchise, remains unaffected and expects to have 15 ongoing Phase 3 oncology trials by year end, with multiple late-stage data readouts in 2026. Sahin and Türeci are expected to transition to the new company’s management by the end of 2026, while BioNTech’s Supervisory Board has started searching for their successors.
BioNTech SE insider Ugur Sahin has filed a Form 144 indicating an intent to sell 858,209 American Depositary Shares (ADS), representing ordinary shares with no par value. The planned sale through Berenberg Capital Markets LLC on the Nasdaq Global Select Market has an aggregate market value of $93,870,900.42, while 240,455,450 ADS were outstanding.
The securities to be sold were acquired via stock option exercises on 11/21/2022 (856,186 ordinary shares) and 08/09/2024 (2,023 ordinary shares). Over the past three months, Sahin has already sold multiple ADS blocks, including 72,970 ADS for $7,901,797.25 on 01/14/2026 and 62,000 ADS for $7,451,792.40 on 01/22/2026.
BioNTech SE announced that its Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer, effective March 1, 2026. This is a newly created role focused on leading the company’s global people strategy.
The appointment supports BioNTech’s strategy to evolve into a multi-product oncology company by 2030, emphasizing the importance of its global, highly skilled workforce. Jimenez brings more than 20 years of international HR experience from Georg Fischer, Toyota, Johnson & Johnson, and General Mills, and will be based at BioNTech’s headquarters in Mainz, Germany.